LRRK2 (leucine-rich repeat kinase 2) is a large, multi-domain protein with both kinase and GTPase activity. Pathogenic mutations in LRRK2 — particularly G2019S ( accounts for 5-6% of familial PD and 1-3% of sporadic PD) — cause hyperactivation of its kinase domain, leading to increased phosphorylation of downstream targets that disrupt multiple cellular processes including autophagy, lysosomal function, synaptic vesicle trafficking, and mitochondrial homeostasis[@izzard2024, @blauwendraat2020].
LRRK2 is a 2527-amino acid protein containing multiple functional domains:
| Domain | Position | Function |
|---|---|---|
| Armadillo repeats | N-terminal | Protein-protein interactions |
| Ankyrin repeats | N-terminal | Scaffold for complex formation |
| Leucine-rich repeats (LRR) | Residues 980-1250 | Protein interactions, regulatory |
| COR (C-terminal of Roc) | 1275-1505 | Dimerization, GTPase regulation |
| ROC (Roc domain) | 1510-1855 | GTP binding, hydrolyzes to GDP |
| ML (MAPKKK-like) | 1885-2000 | Kinase activity |
| Kinase domain | 2000-2150 | Phosphorylates substrates |
| WD40 repeats | C-terminal | Protein interactions |
The kinase activity of LRRK2 is tightly regulated by multiple mechanisms:
| Mutation | Domain | Effect on Kinase Activity | Population Frequency |
|---|---|---|---|
| G2019S | Kinase (activation loop) | Gain-of-function; 2-3x increase | 5-6% familial PD, 1-3% sporadic |
| R1441C/H/G | COR domain | Variable; affects GTPase | 1-2% familial PD |
| N1437H | COR domain | Gain-of-function | Rare |
| Y1699C | ROC domain | Variable | Rare |
| I2020T | Kinase (DFG motif) | Gain-of-function | <1% familial PD |
The G2019S mutation replaces glycine (small, flexible) with serine (polar, larger) in the DFG+1 position of the kinase activation loop. This structural change:
LRRK2 phosphorylates multiple proteins involved in cellular homeostasis:
| Substrate | Function | Effect of LRRK2 Phosphorylation |
|---|---|---|
| Rab GTPases (Rab3, Rab5, Rab8, Rab10, Rab12, Rab29, Rab35, Rab43) | Vesicle trafficking | Alters trafficking kinetics, disrupts endosomal/lysosomal function |
| MNK1/2 | Translation regulation | Unknown functional consequence |
| ERK1/2 | MAPK signaling | Enhanced activation |
| Akt | Cell survival | Altered signaling |
| GSK3β | Tau phosphorylation | May increase tau pathology |
| CSNK1D | Casein kinase 1 delta | Altered circadian regulation |
Phosphorylation of Rab GTPases by LRRK2 is the most functionally significant downstream effect of LRRK2 hyperactivity:
LRRK2 G2019S disrupts autophagy at multiple steps:
The convergence of LRRK2 hyperactivity and autophagy dysfunction provides a mechanistic link between LRRK2 mutations and the accumulation of alpha-synuclein aggregates.
LRRK2 mutations affect mitochondrial dynamics:
LRRK2 is highly expressed at synapses and regulates:
Microglial LRRK2 regulates inflammatory responses:
The LRRK2 pathway intersects with alpha-synuclein pathology in multiple ways:
LRRK2 mutations and tau pathology frequently co-occur:
| LRRK2 Mutation | Alpha-Synuclein Pathology | Tau Pathology | Other |
|---|---|---|---|
| G2019S | 70-80% (Lewy bodies) | Variable | Some TDP-43 |
| R1441C/H | ~50-60% | Less common | — |
| N1437H | Variable | — | — |
The phosphorylation of Rab GTPases by hyperactive LRRK2 is now recognized as a central mechanism driving neurodegeneration in LRRK2-linked PD[1]. Rab GTPases function as molecular switches controlling vesicle trafficking, and their phosphorylation by LRRK2 alters their guanine nucleotide state, effector interactions, and subcellular localization.
Rab10 is the best-characterized LRRK2 substrate in neurons. Phosphorylation at T73 (in the switch I region) converts Rab10 to a state that preferentially binds its guanine nucleotide, preventing normal GDP-bound/GTP-bound cycling. This disrupts:
Rab29 (Rab7L1) is unique among LRRK2 substrates in that it can recruit LRRK2 to specific organelles. When Rab29 is phosphorylated by hyperactive LRRK2, it triggers LRRK2 accumulation at the Golgi apparatus, causing Golgi fragmentation and disrupting organelle trafficking. This provides a mechanistic link between LRRK2 mutations and the secretory pathway defects observed in PD neurons.
Rab8a phosphorylation regulates primary cilium function and cell polarity. LRRK2 mutations disrupt ciliogenesis, which may affect neuronal development and repair.
Rab3 (multiple isoforms A, B, C, D) phosphorylation at presynaptic terminals disrupts synaptic vesicle release probability and replenishment kinetics. LRRK2 G2019S neurons show reduced dopamine release amplitude and increased release variability.
The LRRK2 inhibitor DNL151 (also known as BIIB122, developed by Denali Therapeutics with Biogen) represents the most advanced LRRK2-targeted therapy. The Phase 1 study (NCT04056689) enrolled 172 healthy volunteers and demonstrated[@heaton2023, @dnl2024]:
| Finding | Result |
|---|---|
| Target engagement | Dose-dependent reduction in pS935 LRRK2 in peripheral blood mononuclear cells (PBMCs) |
| Biomarker response | >50% reduction in pRab10 at highest doses |
| Safety | Well-tolerated; no serious adverse events |
| Pharmacokinetics | BBB-penetrant; plasma half-life supports once-daily dosing |
The LIGHTHOUSE trial (NCT05348785) is a Phase 3, randomized, double-blind, placebo-controlled study evaluating BIIB122 in patients with PD who carry the LRRK2 G2019S mutation. Key details:
Phase 2/3 considerations: Based on the Phase 1 results, the development program uses doses that achieve >50% pRab10 inhibition in PBMCs, which may also inhibit phosphorylation in the CNS. The biomarker approach allows pharmacodynamic monitoring without invasive brain sampling.
Biomarker strategy for LRRK2 inhibitor trials:
| Biomarker | Source | Rationale | Status |
|---|---|---|---|
| pS935 LRRK2 | PBMCs | Direct measure of target engagement | Validated |
| pRab10 (T73) | PBMCs | Downstream pathway biomarker | Validated |
| pS129 alpha-synuclein | CSF | Disease modification signal | Exploratory |
| Neurofilament light chain (NfL) | CSF, blood | Neurodegeneration biomarker | Exploratory |
| Dopamine terminal density | DAT PET | Neuroprotection signal | Exploratory |
LRRK2 mutations provide strong genetic validation for this therapeutic approach[@paisan2019, @blauwendraat2020]:
Patient selection considerations:
LRRK2 G2019S causes profound defects in the autophagy-lysosome pathway, a major mechanism of neurodegeneration[2]:
Autophagy initiation defects: LRRK2 phosphorylates components of the PI3K complex (VPS34, Beclin-1), reducing initiation of autophagosome formation.
Vesicle trafficking disruption: Rab10 and Rab8 phosphorylation by hyperactive LRRK2 blocks the trafficking of autophagosomes toward lysosomes. Live-cell imaging in patient iPSC-derived neurons shows stalled autophagosomes that fail to fuse with lysosomes.
Lysosomal dysfunction: LRRK2 G2019S neurons show reduced lysosomal acidification, decreased cathepsin activity, and impaired lysosomal calcium release. This creates a feedforward loop: impaired autophagy leads to aggregate accumulation, which further stresses the lysosomal system.
Mitophagy defects: LRRK2 phosphorylates Rab proteins that regulate PINK1/Parkin-mediated mitophagy. Mitochondria in LRRK2 G2019S neurons show reduced quality control, elevated reactive oxygen species (ROS), and membrane potential loss.
Synaptic pathology is an early feature of LRRK2-associated PD:
Presynaptic terminals: LRRK2 is highly enriched at synapses where it regulates vesicle release. G2019S mutations cause:
Postsynaptic changes: G2019S neurons show altered NMDA receptor trafficking, reduced PSD-95 expression, and impaired long-term potentiation (LTP) in mouse models.
Electron microscopy: Post-mortem tissue from LRRK2 G2019S carriers shows reduced synaptic density and altered synaptic morphology in the substantia nigra.
Microglia express high levels of LRRK2, particularly in disease states:
This suggests LRRK2 inhibitors may have dual benefits: protecting neurons directly while also suppressing toxic microglial activation.
| Compound | Company | Stage | Notes |
|---|---|---|---|
| DNL151 (BIIB122) | Denali/Biogen | Phase 3 (NCT05348785) | LRRK2 inhibitor, BBB-penetrant |
| BIIB122 | Denali/Biogen | Phase 3 | Same as DNL151 |
| JM-10 | The Michael J. Fox Foundation | Preclinical | CNS-penetrant |
| GZ-2199893 | GlaxoSmithKline | Preclinical | Early LRRK2 inhibitor |
| XL-142 | — | Preclinical | Selective inhibitor |
Key development: Denali's DNL151/BIIB122 completed Phase 1 showing dose-dependent reduction in pS935 LRRK2 (pharmacodynamic biomarker) with good tolerability. Phase 3 LIGHTHOUSE trial in G2019S carriers ongoing.
| Approach | Mechanism | Status |
|---|---|---|
| ASO therapy | Reduce LRRK2 mRNA | Preclinical |
| Protein degraders | PROTAC for LRRK2 | Discovery |
| GTPase modulators | Enhance GTPase activity to reduce kinase | Preclinical |
| Rab-directed | Inhibit downstream Rab phosphorylation | Research |
| Biomarker | Source | Response to Inhibition |
|---|---|---|
| pS935 LRRK2 | PBMCs, lymphocytes | Decreases with LRRK2 inhibitor |
| pRab10 (T73) | PBMCs, brain tissue | Decreases with inhibition |
| Total LRRK2 | PBMCs | Unchanged |
| pS129 alpha-synuclein | CSF | May decrease with sustained inhibition |
LRRK2 and Rab proteins in health and disease. Trends Mol Med. 2024. ↩︎
Loss of LRRK2 impairs lysosomal and autophagic function in iPSC-derived neurons. Neurobiol Dis. 2022. ↩︎